Alpha Tau Medical Selected to Present at the Biotech Showcase™ 2018
Tel Aviv - Alpha Tau Medical is thrilled to announce that it was selected to present its highly precise and effective Alpha DaRT radiotherapy treatment for solid cancer at the Biotech Showcase™ during J.P. Morgan Healthcare Conference in January 2018.
Alpha Tau Medical is a medical device company focusing on R&D and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer.
The Alpha DaRT outpatient treatment enables highly potent and conformal radiation for solid cancer. It spares the surrounding healthy tissue and research has not shown negative systemic effects. In addition, the treatment can be delivered in about 60 min within a single session in any kind of treatment room. After a short period of merely 15 days, the treatment is completed. On top of that, the technology has been shown to be safe and effective for various types of tumors including such which are radio-resistant.
The company is now running its firsts clinical trials with very promising preliminary results in Israel and Italy. Leading cancer centers such as MSKCC in the USA, NCI in Japan, and others are currently initiating clinical studies for new indications.
Uzi Sofer, CEO of Alpha Tau Medical, will present the revolutionary Alpha DaRT radiotherapy treatment for solid cancer at the Biotech Showcase 2018. Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that Alpha Tau Medical will be presenting at Biotech Showcase this year”. The presentation will take place as follows:
Date: Tuesday, January 10th, 2018
Time: 10:30 am PST
Venue: Green Room, Grand Ballroom Level,
Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA
Biotech Showcase™, is part of the J.P. Morgan Annual Healthcare Conference. Being one of the industry's largest annual healthcare investor conferences, it is devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place.